Wedbush Maintains Outperform on Tango Therapeutics, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll maintains an Outperform rating on Tango Therapeutics (NASDAQ:TNGX) but lowers the price target from $18 to $11.
May 23, 2024 | 4:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Wedbush analyst Robert Driscoll maintains an Outperform rating on Tango Therapeutics but lowers the price target from $18 to $11.
The Outperform rating suggests a positive outlook, but the lowered price target indicates reduced expectations for short-term growth. This mixed signal may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100